world-nutrition-2018-scientifictracks

5 / 20

World Nutrition 2018
J u n e 1 8 - 1 9 , 2 0 1 8
P a r i s , F r a n c e
Page 25
Journal of Clinical Nutrition & Dietetics
ISSN 2472-1921
W o r l d C o n g r e s s o n
Nutrition and Dietetics
Obesity affects one billion people and impairs all aspects of health. Success
rates for maintaining long-term weight loss are very low, thus there is
an acute need for more effective treatment strategies. The natural appetite
inhibiting hormone glucagon-like-peptide-1 (GLP-1) is secreted from the
intestine upon meal intake and reduces blood glucose and food intake. Obese
people have low levels of GLP-1, but interestingly a sustained weight loss of
10 kg for one year induces a marked increase in GLP-1. Thus, high levels of
GLP-1 seem to be part of successful weight loss maintenance. Treatment with
GLP-1 analogues facilitates long term weight loss maintenance accompanied
by substantial improvement in metabolic health, compared to similar weight
loss obtained by conventional dietary-regimes. Furthermore, obese people can
be grouped into high and low immuno-metabolic risk profiles by analyzing the
full plasma proteomic profile, which opens up for more personalized treatment
strategies. Finally, patients with the genetic heart disease Long QT Syndrome
have exaggerated GLP-1 secretion and endocrine pancreatic dysfunction after
sugar intake and thereby increased risk of serious hypoglycemia. Therefore,
large amounts of sugar intake should be avoided. Conclusively, normalized
GLP-1 levels are crucial for both body weight and glucose regulation in humans.
Obesity, appetite-regulation and how to maintain a healthy weight loss - the
biological mechanisms behind healthy sustained weight loss in humans
Signe Sorensen Torekov
University of Copenhagen, Denmark
Signe Sorensen Torekov, J Clin Nutr Diet 2018 Volume: 4
DOI: 10.4172/2472-1921-C1-002
Biography
Signe Torekov is a human biologist with a strong background
in clinical metabolic translational research combining basic
metabolic genetics, physiology and treatment in humans. Her
workhastogetherwithherresearchgroupalreadymadeseminal
contributions to the understanding of humanmetabolism.Thus,
the work has succeeded in showing the beneficial treatment
potentials besides weight loss, for the appetite-inhibiting
hormone GLP-1 in the alarming global epidemic of obesity.
Furthermore, she has pinpointed the important link between
Long QT Syndrome and risk of hypoglycemia thereby creating
awareness of avoiding hypoglycemia by reducing sugar intake
in these patients. Finally she has created a novel experimental
approachforclinicaltranslationalmetabolism inorderto identify
novel markers and predictors for human metabolic health.
Signe Torekov´s research papers are currently being published
in high-ranked international journals and she has obtained high-
level funding for her research (more than €3.1 million during the
last three years). In total, she has authored 44 peer-reviewed
papers, much of this work has been published in high-ranking
journals in the field (Cell Metabolism, Circulation, Diabetes,
JCEM, Diabetologia, DOM, and Molecular Systems Biology
with13 first and 16 last authorships), h-index of 16 and a total of
1022 citations (Web of Science, May 2017). Signe Torekov has
received the prestigious Anders Jahre Young Medical Award of
€26.000 as a personal award (also called “the young Nobel Prize
in Medicine”) in 2017. The prize was awarded “in recognition of
Dr Torekovs´s outstanding scientific work. Besides that she has
received several Young Investigator Awards and in 2016, she
received the prestigious Novo Nordisk Foundation Excellence
Fellowship of €673.000 given to excellent young researchers
within endocrinology in the Nordic Countries. In 2015, she
formed an international alliance in immuno-metabolism with
top researchers at Oxford and Karolinska University. Together
they received €5.4 million from the Novo Nordisk Foundation
to identify newmarkers and treatment in immuno-metabolism